GILD
Gilead Sciences, Inc.
—
123.76 $
-1.6900 (%-1.35)
Previous Close: 125.45
Day Low₺122.43
Day High₺126.39
GILD: Gilead Sciences, Inc. Financials
GILD Income Statement
Total revenue
Net income
Gross margin TTM
78.83%
Operating margin TTM
39.74%
Net profit margin TTM
28.9%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 29,442,000,000 | 28,754,000,000 | 27,116,000,000 | 27,281,000,000 |
| Operating income | 11,701,000,000 | 1,662,000,000 | 7,605,000,000 | 7,330,000,000 |
| Net income | 8,510,000,000 | 480,000,000 | 5,665,000,000 | 4,592,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 29,442,000,000 | 28,754,000,000 | 27,116,000,000 | 27,281,000,000 |
| Cost of revenue | 6,234,000,000 | 6,251,000,000 | 6,498,000,000 | 5,657,000,000 |
| Gross profit | 23,208,000,000 | 22,503,000,000 | 20,618,000,000 | 21,624,000,000 |
| Research and development expenses | 5,799,000,000 | 5,907,000,000 | 5,718,000,000 | 4,977,000,000 |
| General and administrative expenses | 2,186,000,000 | 2,638,000,000 | 2,818,000,000 | 4,895,000,000 |
| Selling and marketing expenses | 3,522,000,000 | 3,453,000,000 | 3,272,000,000 | 778,000,000 |
| Selling, general and administrative expenses | 5,708,000,000 | 6,091,000,000 | 6,090,000,000 | 5,673,000,000 |
| Other expenses | 0 | 8,843,000,000 | 1,205,000,000 | 3,644,000,000 |
| Operating expenses | 11,507,000,000 | 20,841,000,000 | 13,013,000,000 | 14,294,000,000 |
| Cost and expenses | 17,741,000,000 | 27,092,000,000 | 19,511,000,000 | 19,951,000,000 |
| Net interest income | -675,000,000 | -696,000,000 | -568,000,000 | -829,000,000 |
| Interest income | 349,000,000 | 281,000,000 | 376,000,000 | 106,000,000 |
| Interest expense | 1,024,000,000 | 977,000,000 | 944,000,000 | 935,000,000 |
| Depreciation and amortization | 2,760,000,000 | 2,767,000,000 | 2,693,000,000 | 2,103,000,000 |
| EBITDA | 13,580,000,000 | 4,434,000,000 | 10,496,000,000 | 8,852,000,000 |
| EBIT | 10,820,000,000 | 1,667,000,000 | 7,803,000,000 | 6,749,000,000 |
| Non-operating income (excl. interest) | 881,000,000 | -5,000,000 | -198,000,000 | 581,000,000 |
| Operating income | 11,701,000,000 | 1,662,000,000 | 7,605,000,000 | 7,330,000,000 |
| Total other income/expenses (net) | -1,905,000,000 | -972,000,000 | -746,000,000 | -1,516,000,000 |
| Income before tax | 9,796,000,000 | 690,000,000 | 6,859,000,000 | 5,814,000,000 |
| Income tax expense | 1,286,000,000 | 211,000,000 | 1,247,000,000 | 1,248,000,000 |
| Net income from continuing operations | 8,510,000,000 | 479,000,000 | 5,612,000,000 | 4,566,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 0 | 1,000,000 | 1,000,000 | 0 |
| Net income | 8,510,000,000 | 480,000,000 | 5,665,000,000 | 4,592,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 8,510,000,000 | 480,000,000 | 5,665,000,000 | 4,592,000,000 |
| EPS | 7 | 0.38 | 5 | 4 |
| Diluted EPS | 7 | 0.38 | 5 | 4 |
| Weighted average shares outstanding | 1,244,000,000 | 1,247,000,000 | 1,248,000,000 | 1,255,000,000 |
| Weighted average diluted shares outstanding | 1,255,000,000 | 1,255,000,000 | 1,258,000,000 | 1,262,000,000 |